Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR - PubMed (original) (raw)
Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR
Ajay Pandita et al. Genes Chromosomes Cancer. 2004 Jan.
Abstract
Despite the high incidence of EGFR amplification in patient glioblastoma multiforme (GBM) tissues, only a single GBM cell line, of the many described in the literature, is known to contain and maintain amplified EGFR. Because EGFR mutations in GBM manifest primarily, if not exclusively, in amplified form, it follows that the availability of cell lines with mutation of endogenous EGFR would also be in short supply. In fact, there are no GBM cell lines harboring the common EGFR mutants described in patient GBMs. These observations suggest that in vivo environments select for EGFR amplification, whereas in vitro environments, specifically cell cultures, select against this gene alteration. To contrast directly the fates of EGFR amplification in vivo and in vitro, as well as to examine potential relationships between EGFR amplification and mutation, we have established and maintained GBM explants as xenografts by serial passaging in nude mice. Analysis of EGFR copy number and EGFR mutation status in 11 patient tumors and their corresponding xenografts, as well as the monitoring of EGFR copy number during the establishment of a GBM cell line from a xenograft with amplified EGFR, indicated that selection for EGFR amplification is an in vivo phenomenon. Furthermore, our data indicated that EGFR mutation occurs only in tumors with EGFR amplification and showed that the selection of amplified mutant EGFR over amplified wild-type EGFR as a xenograft occurred rapidly and completely during tumor propagation.
Copyright 2003 Wiley-Liss, Inc.
Similar articles
- Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts.
Bigner SH, Humphrey PA, Wong AJ, Vogelstein B, Mark J, Friedman HS, Bigner DD. Bigner SH, et al. Cancer Res. 1990 Dec 15;50(24):8017-22. Cancer Res. 1990. PMID: 2253244 - Glioblastoma stem-like cell lines with either maintenance or loss of high-level EGFR amplification, generated via modulation of ligand concentration.
Schulte A, Günther HS, Martens T, Zapf S, Riethdorf S, Wülfing C, Stoupiec M, Westphal M, Lamszus K. Schulte A, et al. Clin Cancer Res. 2012 Apr 1;18(7):1901-13. doi: 10.1158/1078-0432.CCR-11-3084. Epub 2012 Feb 7. Clin Cancer Res. 2012. PMID: 22316604 - The EGFRvIII variant in glioblastoma multiforme.
Gan HK, Kaye AH, Luwor RB. Gan HK, et al. J Clin Neurosci. 2009 Jun;16(6):748-54. doi: 10.1016/j.jocn.2008.12.005. Epub 2009 Mar 25. J Clin Neurosci. 2009. PMID: 19324552 Review. - EGFR heterogeneity and implications for therapeutic intervention in glioblastoma.
Eskilsson E, Røsland GV, Solecki G, Wang Q, Harter PN, Graziani G, Verhaak RGW, Winkler F, Bjerkvig R, Miletic H. Eskilsson E, et al. Neuro Oncol. 2018 May 18;20(6):743-752. doi: 10.1093/neuonc/nox191. Neuro Oncol. 2018. PMID: 29040782 Free PMC article. Review.
Cited by
- Multi-omics and pharmacological characterization of patient-derived glioma cell lines.
Wu M, Wang T, Ji N, Lu T, Yuan R, Wu L, Zhang J, Li M, Cao P, Zhao J, Li G, Li J, Li Y, Tang Y, Gao Z, Wang X, Cheng W, Ge M, Cui G, Li R, Wu A, You Y, Zhang W, Wang Q, Chen J. Wu M, et al. Nat Commun. 2024 Aug 8;15(1):6740. doi: 10.1038/s41467-024-51214-y. Nat Commun. 2024. PMID: 39112531 Free PMC article. - DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines.
Schniederjan MJ, Potnis C, Vasudevaraja V, Moser CD, Watson B, Snuderl M, MacDonald T, Rogers BB. Schniederjan MJ, et al. Children (Basel). 2024 Apr 20;11(4):492. doi: 10.3390/children11040492. Children (Basel). 2024. PMID: 38671709 Free PMC article. - Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.
Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP, Carter BS, Curry WT, Dunn GP, Frigault MJ, Gerstner ER, Ghannam JY, Kann MC, Larson RC, Leick MB, Nahed BV, Richardson LG, Scarfò I, Sun J, Wakimoto H, Maus MV, Choi BD. Schmidts A, et al. Neurooncol Adv. 2022 Dec 22;5(1):vdac185. doi: 10.1093/noajnl/vdac185. eCollection 2023 Jan-Dec. Neurooncol Adv. 2022. PMID: 36751672 Free PMC article. - Comparing tumor microRNA profiles of patients with long‑ and short‑term‑surviving glioblastoma.
Schneider B, Lamp N, Zimpfer A, Henker C, Erbersdobler A. Schneider B, et al. Mol Med Rep. 2023 Jan;27(1):8. doi: 10.3892/mmr.2022.12895. Epub 2022 Nov 11. Mol Med Rep. 2023. PMID: 36367159 Free PMC article. - Therapeutic Potential of Cannabinoids on Tumor Microenvironment: A Molecular Switch in Neoplasia Transformation.
Bakshi HA, Faruck HL, Ravesh Z, Ansari P, Hannan JMA, Hashimoto R, Takayama K, Farzand R, Nasef MM, Mensah A, Aljabali AAA, Mishra V, Charbe NB, Goyal R, Negi P, Serrano-Aroca Á, Bahar B, El-Tanani M, Courtenay AJ, McCarron P, Jack IG, Tambuwala MM. Bakshi HA, et al. Integr Cancer Ther. 2022 Jan-Dec;21:15347354221096766. doi: 10.1177/15347354221096766. Integr Cancer Ther. 2022. PMID: 35796303 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous